Clinical Trial: RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07413939) titled 'RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive' on Feb. 10.

Brief Summary: The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: HER2-positive Breast Cancer

Intervention: DRUG: RO7771950

Participants will receive one of two doses of RO7771950 orally (PO) twice a day (BI...